In humans, therapy inducing osteoclast apoptosis [18] and RANKL-inhibitors aiming to inhibit osteoclast differentiation and activation is frequently used among prostate cancer patients in order to increase bone strength and decrease bone fractures. The gene discussed is TNFSF11; the disease is Familial prostate cancer.